BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561. [PMID: 12794717 DOI: 10.1002/jmv.10430] [Cited by in Crossref: 149] [Cited by in F6Publishing: 138] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
2 Kim HY, Yoo JJ, Oh S, Yu SJ, Kim YJ, Yoon JH, Kim W, Jung YJ, Kim BH, Kim CM, Park JW, Lee JH. Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. J Med Virol. 2018;90:1593-1603. [PMID: 29900560 DOI: 10.1002/jmv.25241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tsai SH, Dai MS, Yu JC, Ho CL, Chen YC, Wu YY, Chang PY, Kao WY, Chao TY. Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine. Support Care Cancer 2011;19:1779-87. [PMID: 20927554 DOI: 10.1007/s00520-010-1019-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
4 Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113:3147-3153. [PMID: 19144986 DOI: 10.1182/blood-2008-10-163493] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 7.6] [Reference Citation Analysis]
5 Tsai FC, Hsieh SC, Chen DS, Sheu JC, Chen CH. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci. 2006;51:1627-1632. [PMID: 16927141 DOI: 10.1007/s10620-006-9074-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
6 Pei SN, Chen CH. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leuk Lymphoma 2015;56:1611-8. [PMID: 25248874 DOI: 10.3109/10428194.2014.964699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yang Y, Du Y, Luo WX, Li C, Chen Y, Cheng K, Ding J, Zhou Y, Ge J, Yang X. Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy. Cancer Chemother Pharmacol. 2015;75:783-790. [PMID: 25687988 DOI: 10.1007/s00280-015-2700-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
8 Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20. [DOI: 10.1002/hep.21051] [Cited by in Crossref: 339] [Cited by in F6Publishing: 308] [Article Influence: 21.2] [Reference Citation Analysis]
9 Ling WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013;108:1931-1935. [PMID: 23652302 DOI: 10.1038/bjc.2013.225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
10 Leonard AN, Love BL, Norris LB, Siddiqui SK, Wallam MN, Bennett CL. Screening for viral hepatitis prior to rituximab chemotherapy. Ann Hematol 2016;95:27-33. [PMID: 26382277 DOI: 10.1007/s00277-015-2502-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283x1245024510.1177_1756283x12450245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol. 2011;29:3270-3277. [PMID: 21788556 DOI: 10.1200/jco.2011.35.1635] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
13 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
14 Morillas RM, López Sisamón D. Reactivación de la hepatitis B asociada a agentes inmunodepresores y a quimioterapia. Historia natural, factores de riesgo y recomendaciones para prevenirla. Medicina Clínica 2019;152:107-14. [DOI: 10.1016/j.medcli.2018.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
15 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immuno–suppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6i6.384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Zheng Y, Zhang S, Tan Grahn HM, Ye C, Gong Z, Zhang Q. Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis. Hepat Mon. 2013;13:e6496. [PMID: 23805156 DOI: 10.5812/hepatmon.6496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
17 Yilmaz B, Erdem D, Teker F, Goren I, Yildirim B, Kut E, Sarikaya D, Atay MH, Yucel I. The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours. J Int Med Res 2016;44:627-38. [PMID: 27048386 DOI: 10.1177/0300060516638992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Laiwatthanapaisan R, Sripongpun P, Chamroonkul N, Dechaphunkul A, Sathitruangsak C, Sakdejayont S, Kongkamol C, Piratvisuth T. Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand. Clin Mol Hepatol 2019;25:366-73. [PMID: 31309773 DOI: 10.3350/cmh.2018.0111] [Reference Citation Analysis]
19 Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011;104:559-563. [PMID: 21285992 DOI: 10.1038/bjc.2011.4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
20 Haydon GH, Mutimer DJ. Hepatitis B and C virus infections in the immune compromised: . Current Opinion in Infectious Diseases 2003;16:473-9. [DOI: 10.1097/00001432-200310000-00015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
21 Sun WC, Hsu PI, Yu HC, Lin KH, Tsay FW, Wang HM, Tsai TJ, Chen WC, Lai KH, Cheng JS. The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. PLoS One. 2015;10:e0116978. [PMID: 25658926 DOI: 10.1371/journal.pone.0116978] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
22 Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? Clin Liver Dis. 2020;24:317-333. [PMID: 32620274 DOI: 10.1016/j.cld.2020.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Guruprasad B, Kavitha S, Aruna Kumari B, Vijaykumar B, Sumati B, Mahua S, Appaji L, Jayshree R. Risk of hepatitis B infection in pediatric acute lymphoblastic leukemia in a tertiary care center from South India: HBV in Pediatric ALL. Pediatr Blood Cancer 2014;61:1616-9. [DOI: 10.1002/pbc.25065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
24 Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619-633. [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
25 Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004;24:540-546. [PMID: 15566502 DOI: 10.1111/j.1478-3231.2004.0964.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 4.1] [Reference Citation Analysis]
26 Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010;116:4769-4776. [PMID: 20597091 DOI: 10.1002/cncr.25253] [Cited by in Crossref: 106] [Cited by in F6Publishing: 97] [Article Influence: 8.8] [Reference Citation Analysis]
27 Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis. J Viral Hepat. 2008;15:89-102. [PMID: 18184191 DOI: 10.1111/j.1365-2893.2007.00902.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 40] [Article Influence: 0.6] [Reference Citation Analysis]
28 Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013. World J Gastroenterol 2014; 20(40): 14581-14588 [PMID: 25356022 DOI: 10.3748/wjg.v20.i40.14581] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
29 Yeo W, Hui EP, Chan ATC, Ho WM, Lam KC, Chan PKS, Mok TSK, Lee JJ, Mo FKF, Johnson PJ. Prevention of Hepatitis B Virus Reactivation in Patients With Nasopharyngeal Carcinoma With Lamivudine. American Journal of Clinical Oncology 2005;28:379-84. [DOI: 10.1097/01.coc.0000159554.97885.88] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
30 Hwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, Lal LS, Vierling JM, Suarez-Almazor ME. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012;8:e32-e39. [PMID: 23180996 DOI: 10.1200/jop.2011.000450] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]
31 Tavakolpour S, Alavian SM, Sali S. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened. Hepat Mon 2016;16:e35810. [PMID: 27257429 DOI: 10.5812/hepatmon.35810] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
32 Liu JY, Sheng YJ, Ding XC, Tang H, Tong SW, Zhang DZ, Zhou Z, Hu P, Liao Y, Ren H. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. J Formos Med Assoc. 2015;114:164-173. [PMID: 25678179 DOI: 10.1016/j.jfma.2012.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
33 Stebbing J, Atkins M, Nelson M, Rajpopat S, Newsom-Davis T, Gazzard B, Bower M. Hepatitis B reactivation during combination chemotherapy for AIDS-related lymphoma is uncommon and does not adversely affect outcome. Blood 2004;103:2431-2. [PMID: 14998920 DOI: 10.1182/blood-2003-12-4222] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
34 Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy: Prevention of HBV reactivation. Hepatology Research 2012;42:627-36. [DOI: 10.1111/j.1872-034x.2012.00998.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
35 Charbel H, Lewis JH. Hepatitis B Reactivation in the Setting of Chemotherapy and Immunosuppression. In: Shetty K, Wu GY, editors. Chronic Viral Hepatitis. Totowa: Humana Press; 2010. pp. 307-36. [DOI: 10.1007/978-1-59745-565-7_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-19. [PMID: 24247262 DOI: 10.1038/nrgastro.2013.216] [Cited by in Crossref: 155] [Cited by in F6Publishing: 137] [Article Influence: 17.2] [Reference Citation Analysis]
37 King LY, Chung RT. When treating cancer, please don't forget hepatitis B. Oncologist 2010;15:826-9. [PMID: 20647389 DOI: 10.1634/theoncologist.2009-0282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
38 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
39 Huang G, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, Fu SY, Wu MC. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg. 2013;257:490-505. [PMID: 22868358 DOI: 10.1097/sla.0b013e318262b218] [Cited by in Crossref: 70] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
40 Voican C, Mir O, Loulergue P, Dhooge M, Brezault C, Dréanic J, Chaussade S, Pol S, Coriat R. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Annals of Oncology 2016;27:2172-83. [DOI: 10.1093/annonc/mdw414] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
41 Shoushtari AH, Shaw RA. Fulminant hepatitis following chemotherapy treatment for breast cancer. BMJ Case Rep 2013;2013:bcr2012007017. [PMID: 23307451 DOI: 10.1136/bcr-2012-007017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Jaillais A, Herber-Mayne A, D'Alteroche L, Landau A, Merrouche Y, Vignot S. [HBV infection: Screening and treatment for oncology patients]. Bull Cancer 2018;105:162-70. [PMID: 29066086 DOI: 10.1016/j.bulcan.2017.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Mandalà M, Fagiuoli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R, Roila F. Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol 2013;87:12-27. [PMID: 23313021 DOI: 10.1016/j.critrevonc.2012.12.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
44 Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, Cho SH, Han JY, Lee YS. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233-240. [PMID: 16440357 DOI: 10.1002/hep.21024] [Cited by in Crossref: 138] [Cited by in F6Publishing: 134] [Article Influence: 8.6] [Reference Citation Analysis]
45 Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22:219-237. [PMID: 27291888 DOI: 10.3350/cmh.2016.0024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
46 Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. Ann Intern Med 2016;164:30-40. [PMID: 26595058 DOI: 10.7326/M15-1121] [Cited by in Crossref: 92] [Cited by in F6Publishing: 37] [Article Influence: 13.1] [Reference Citation Analysis]
47 Wani MA, Sodhi JS, Yatoo GN, Shah A, Geelani S, Zargar SA, Gulzar GM, Khan M, Aziz SA. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy. J Clin Exp Hepatol 2020;10:590-8. [PMID: 33311896 DOI: 10.1016/j.jceh.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Lee YM, Francis K, Walker J, Lee SM. What are the information needs of Chinese breast cancer patients receiving chemotherapy? European Journal of Oncology Nursing 2004;8:224-33. [DOI: 10.1016/j.ejon.2003.12.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
49 Thompson PA, Tam CS, Thursky K, Seymour JF. Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leuk Lymphoma 2010;51:1592-5. [PMID: 20807092 DOI: 10.3109/10428194.2010.509456] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
50 Yang C, Cao H, Guo Y, Feng Y, Zhang N. Identification of Novel Breast Cancer Genes based on Gene Expression Profiles and PPI Data. CP 2019;16:415-26. [DOI: 10.2174/1570164616666190126111354] [Reference Citation Analysis]
51 Chaulet P. Tuberculosis: a six-month cure. World Health Forum. 1989;10:116-122. [PMID: 2665766 DOI: 10.1016/j.critrevonc.2015.10.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
52 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Doyle J, Raggatt M, Slavin M, Mclachlan S, Strasser SI, Sasadeusz JJ, Howell J, Hajkowicz K, Nandurkar H, Johnston A, Bak N, Thompson AJ. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Medical Journal of Australia 2019;210:462-8. [DOI: 10.5694/mja2.50160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
54 Yoon EL. [Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients]. Korean J Gastroenterol 2019;74:258-66. [PMID: 31765554 DOI: 10.4166/kjg.2019.74.5.258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Idilman R, Arat M. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther 2011;9:641-52. [PMID: 21819330 DOI: 10.1586/eri.11.79] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
56 Saich R, Chapman R. What's new in … Liver disorders: part 2. Medicine 2002;30:1-3. [DOI: 10.1383/medc.2002.30.11.v] [Reference Citation Analysis]
57 Han JW, Yang H, Lee HL, Bae SH, Choi JY, Lee JW, Kim HJ, Lee S, Cho SG, Min CK, Kim DW, Yoon SK. Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. Hepatol Res 2016;46:657-68. [PMID: 26445232 DOI: 10.1111/hepr.12603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
58 Baghbanian M, Halvani M, Roghani HS, Lotfi MH, Yazdi MF, Vahedian-Ardakani HA. PREVALENCE OF OCCULT HEPATITIS B INFECTION IN IRANIAN CANCER PATIENTS BEFORE CHEMOTHERAPY TREATMENT. Arq Gastroenterol 2016;53:175-9. [PMID: 27438423 DOI: 10.1590/S0004-28032016000300010] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
59 Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Nat Rev Clin Oncol. 2012;9:156-166. [PMID: 22271089 DOI: 10.1038/nrclinonc.2012.1] [Cited by in Crossref: 107] [Cited by in F6Publishing: 90] [Article Influence: 10.7] [Reference Citation Analysis]
60 Su YC, Lin PC, Yu HC, Wu CC. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy. Eur J Gastroenterol Hepatol. 2018;30:925-929. [PMID: 29621049 DOI: 10.1097/meg.0000000000001130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
61 Türker K, Albayrak M, Öksüzoğlu B, Balc E, Oğan MC, Iskender G, Altuntaş F. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature. Eur J Gastroenterol Hepatol 2015;27:39-45. [PMID: 25076063 DOI: 10.1097/MEG.0000000000000115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
62 Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Koizumi W. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med. 2010;21:333-337. [PMID: 20603047 DOI: 10.1016/j.ejim.2010.04.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
63 Yao Z, Liao W, Ho C, Chen K, Shih J, Chen J, Lin Z, Lin C, Yang JC, Yu C. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients. European Journal of Cancer 2019;117:107-15. [DOI: 10.1016/j.ejca.2019.05.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
64 Li YR, Chen WC, Tsai WL, Cheng JS, Tsay FW, Kao SS, Chen HC, Hsu PI. Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy without antiviral prophylaxis.J Viral Hepat. 2020;27:873-879. [PMID: 32301253 DOI: 10.1111/jvh.13302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Ludwig E. HBV reactivation in immunosuppressed patients: prevention or containment? Hepatology. 2014;59:2062-2064. [PMID: 24753022 DOI: 10.1002/hep.27056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
66 Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol 2014; 20(24): 7675-7685 [PMID: 24976705 DOI: 10.3748/wjg.v20.i24.7675] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
67 Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis. 2007;11:965-991. [PMID: 17981237 DOI: 10.1016/j.cld.2007.08.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
68 Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88:209-215. [PMID: 15609123 DOI: 10.1007/s10549-004-0725-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 4.3] [Reference Citation Analysis]
69 Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol 2015; 7(7): 954-967 [PMID: 25954478 DOI: 10.4254/wjh.v7.i7.954] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
70 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075. [PMID: 17393513 DOI: 10.1002/hep.21627] [Cited by in Crossref: 407] [Cited by in F6Publishing: 371] [Article Influence: 27.1] [Reference Citation Analysis]
71 Kim MK, Ahn JH, Kim SB, Im YS, Lee SI, Ahn SH, Son BH, Gong G, Kim HH, Kim WK. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med 2007;22:237-43. [PMID: 18309681 DOI: 10.3904/kjim.2007.22.4.237] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
72 Ting SW, Chen YC, Huang YH. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Clin Drug Investig. 2018;38:873-880. [PMID: 29968197 DOI: 10.1007/s40261-018-0671-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
73 Al-Mansour MM, Alghamdi SA, Alsubaie MA, Alesa AA, Khan MA. Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma. Infect Agent Cancer 2018;13:18. [PMID: 29977329 DOI: 10.1186/s13027-018-0190-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
74 Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004;83:769-774. [PMID: 15338194 DOI: 10.1007/s00277-004-0899-y] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 5.7] [Reference Citation Analysis]
75 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283X12450245] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
76 Faraci M, Cappelli B, Lanino E, Morreale G, Fioredda F, Giudice CL, Giacchino R. Hepatitis B reactivation in allogeneic hemopoietic stem cell transplantation setting: A pediatric experience. Pediatric Transplantation 2009;13:923-6. [DOI: 10.1111/j.1399-3046.2008.01080.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
77 Aubourg A, d’Alteroche L, Senecal D, Gaudy C, Bacq Y. [Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation]. Gastroenterol Clin Biol. 2007;31:97-99. [PMID: 17273140 DOI: 10.1016/s0399-8320(07)89335-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
78 Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007;37:705-712. [PMID: 17894766 DOI: 10.1111/j.1445-5994.2007.01479.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 4.7] [Reference Citation Analysis]
79 Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013;13:534. [PMID: 24209764 DOI: 10.1186/1471-2407-13-534] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
80 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
81 Shih CA, Chen WC, Yu HC, Cheng JS, Lai KH, Hsu JT, Chen HC, Hsu PI. Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis. PLoS One. 2015;10:e0132426. [PMID: 26274393 DOI: 10.1371/journal.pone.0132426] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
82 Day FL, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 2011;7:141-7. [PMID: 21886492 DOI: 10.1200/JOP.2010.000133] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
83 Jun BG, Kim YD, Kim SG, Kim YS, Jeong SW, Jang JY, Lee SH, Kim HS, Kang SH, Kim MY, Baik SK, Lee M, Kim TS, Choi DH, Choi SH, Suk KT, Kim DJ, Cheon GJ. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study. PLoS One. 2018;13:e0201316. [PMID: 30059513 DOI: 10.1371/journal.pone.0201316] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
84 Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561. [PMID: 12794717 DOI: 10.1002/jmv.10430] [Cited by in Crossref: 149] [Cited by in F6Publishing: 138] [Article Influence: 7.8] [Reference Citation Analysis]
85 Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22:346-352. [PMID: 25220947 DOI: 10.1111/jvh.12305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
86 Zhong S, Yeo W, Schroder C, Chan PK, Wong WL, Ho WM, Mo F, Zee B, Johnson PJ. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat. 2004;11:55-59. [PMID: 14738558 DOI: 10.1046/j.1352-0504.2003.00467.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 4.1] [Reference Citation Analysis]
87 Li H, Zhang H, Chen L, Chen Y, Chen L, Ren H, Hu H. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2015;39:80-92. [DOI: 10.1016/j.clinre.2014.07.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
88 Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25:864-871. [PMID: 20546439 DOI: 10.1111/j.1440-1746.2010.06243.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
89 Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2:152-162. [PMID: 19669300 DOI: 10.1007/s12072-008-9056-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
90 Ruan J, Li HJ, Sun DX. Reactivation of hepatitis B virus. Shijie Huaren Xiaohua Zazhi 2014; 22(7): 927-932 [DOI: 10.11569/wcjd.v22.i7.927] [Reference Citation Analysis]
91 Hsu PI, Lai KH, Cheng JS, Kao SS, Li YR, Sun WC, Chen WC, Lin KH, Shin CA, Chiang PH, Li YD, Ou WT, Chen HC, Yu HC. Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area. Hepatology. 2015;62:387-396. [PMID: 26041578 DOI: 10.1002/hep.27843] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
92 Louthrenoo W. Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases. Best Practice & Research Clinical Rheumatology 2015;29:319-42. [DOI: 10.1016/j.berh.2015.05.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
93 Ho EY, Yau T, Rousseau F, Heathcote EJ, Lau GK. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int 2015;9:224-30. [PMID: 25788197 DOI: 10.1007/s12072-015-9612-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
94 Xu Z, Dai W, Wu YT, Arshad B, Li X, Wu H, Chen HR, Wu KN, Kong LQ. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis. Eur J Cancer Care (Engl) 2018;27:e12799. [PMID: 29265535 DOI: 10.1111/ecc.12799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
95 Chen WC, Cheng JS, Chiang PH, Tsay FW, Chan HH, Chang HW, Yu HC, Tsai WL, Lai KH, Hsu PI. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy. PLoS One. 2015;10:e0131545. [PMID: 26121480 DOI: 10.1371/journal.pone.0131545] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
96 Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021; 9(21): 5769-5781 [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] [Reference Citation Analysis]
97 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
98 Liu Z, Jiang L, Liang G, Song E, Jiang W, Zheng Y, Gong C. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management. J Viral Hepat 2017;24:561-72. [PMID: 28072494 DOI: 10.1111/jvh.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
99 Huang W, Du L, Tang H. Hepatitis B virus reactivation: overview and management. Future Virology 2021;16:821-35. [DOI: 10.2217/fvl-2021-0275] [Reference Citation Analysis]
100 Gossmann J, Scheuermann EH, Kachel HG, Geiger H, Hauser IA. Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution. Clin Transplant. 2009;23:431-434. [PMID: 19077081 DOI: 10.1111/j.1399-0012.2008.00936.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
101 Lv JW, Chen YP, Huang XD, Zhou GQ, Chen L, Li WF, Tang LL, Mao YP, Guo Y, Xu RH, Ma J, Sun Y. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area. Cancer 2017;123:3540-9. [PMID: 28493307 DOI: 10.1002/cncr.30775] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
102 Braun-Moscovici Y, Braun M, Saadi T, Markovits D, Nahir MA, Balbir-Gurman A. Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study. J Clin Rheumatol 2016;22:364-8. [PMID: 27660934 DOI: 10.1097/RHU.0000000000000434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
103 Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, Su F, Song E. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat. 2011;127:705-712. [PMID: 21445574 DOI: 10.1007/s10549-011-1455-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
104 Choi J, Lim YS. Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy. J Infect Dis. 2017;216:S778-S784. [PMID: 29156044 DOI: 10.1093/infdis/jix178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
105 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244. e3. [PMID: 25447852 DOI: 10.1053/j.gastro.2014.10.038] [Cited by in Crossref: 274] [Cited by in F6Publishing: 249] [Article Influence: 34.3] [Reference Citation Analysis]
106 Seetharam A, Perrillo R, Gish R. Immunosuppression in Patients with Chronic Hepatitis B. Curr Hepatol Rep. 2014;13:235-244. [PMID: 25101233 DOI: 10.1007/s11901-014-0238-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
107 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
108 Riveiro-Barciela M, Buti M. [Hepatitis B virus infection in pregnancy and the immunosuppressed patient]. Gastroenterol Hepatol 2015;38:31-9. [PMID: 25066320 DOI: 10.1016/j.gastrohep.2014.05.011] [Reference Citation Analysis]
109 Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:925-932. [PMID: 20480515 DOI: 10.1002/ibd.21284] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
110 Tan G, Zhou K, Tan CH, Matchar DB, Farid M, Quek R, Ngeow J. Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors. J Glob Oncol 2016;2:186-99. [PMID: 28717701 DOI: 10.1200/JGO.2015.001669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Thio C, Netski D, Myung J, Seaberg E, Thomas D. Changes in Hepatitis B Virus DNA Levels with Acute HIV Infection. CLIN INFECT DIS 2004;38:1024-9. [DOI: 10.1086/382534] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
112 Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152:1297-1309. [PMID: 28219691 DOI: 10.1053/j.gastro.2017.02.009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 214] [Article Influence: 48.2] [Reference Citation Analysis]
113 Kumar M, Sarin SK. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;2:465-95. [DOI: 10.1586/17474124.2.4.465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90:1306-1311. [PMID: 15054446 DOI: 10.1038/sj.bjc.6601699] [Cited by in Crossref: 218] [Cited by in F6Publishing: 215] [Article Influence: 12.1] [Reference Citation Analysis]
115 Liu YC, Hsu CM, Hsiao SY, Hsiao HH. Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. J Pers Med 2021;11:1108. [PMID: 34834460 DOI: 10.3390/jpm11111108] [Reference Citation Analysis]
116 Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol. 2013;28:31-37. [PMID: 23020594 DOI: 10.1111/j.1440-1746.2012.07280.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
117 Cheng J, Pei HH, Sun J, Xie QX, Li JB. Radiation-induced hepatitis B virus reactivation in hepatocellular carcinoma: A case report. Oncol Lett 2015;10:3213-5. [PMID: 26722314 DOI: 10.3892/ol.2015.3724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
118 Jang JW. Management of Patients with Hepatitis B Virus Infection Who Receive Immunosuppressive Treatment or Chemotherapy. Korean J Med 2012;82:149. [DOI: 10.3904/kjm.2012.82.2.149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
119 Federico A, Brancaccio G, Dallio M, Iodice P, Fabozzi A, Del Prete S, Ciardiello F, Loguercio C, Gaeta GB. Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? Dig Liver Dis 2017;49:197-201. [PMID: 27899262 DOI: 10.1016/j.dld.2016.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
120 Nishida T, Hiramatsu N, Mizuki M, Nagatomo I, Kida H, Tazumi K, Shinzaki S, Miyazaki M, Yakushijin T, Tatsumi T, Iijima H, Kiso S, Kanto T, Tsujii M, Takehara T. Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic. Hepatol Res 2013;43:339-46. [PMID: 22882474 DOI: 10.1111/j.1872-034X.2012.01073.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
121 Morrow P, Tarrand J, Taylor S, Kau SC, Theriault R, Hortobagyi G, Broglio K, Hahn K. Effects of chronic hepatitis C infection on the treatment of breast cancer patients. Annals of Oncology 2010;21:1233-6. [DOI: 10.1093/annonc/mdp458] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
122 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
123 Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res 2016;18:10. [PMID: 26810608 DOI: 10.1186/s13058-015-0669-x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 13.3] [Reference Citation Analysis]
124 Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013-2017. [PMID: 19561036 DOI: 10.1093/annonc/mdp230] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 6.2] [Reference Citation Analysis]
125 Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, Guarino M, Biancone L, Caruso A, D'Inca R, Marmo R, Orlando A, Riegler G, Donnarumma L, Camera S, Zorzi F, Renna S, Bove V, Tontini G, Vecchi M, Caporaso N. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat 2013;20:200-8. [PMID: 23383659 DOI: 10.1111/j.1365-2893.2012.01643.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
126 Ogris C, Hu Y, Arloth J, Müller NS. Versatile knowledge guided network inference method for prioritizing key regulatory factors in multi-omics data. Sci Rep 2021;11:6806. [PMID: 33762588 DOI: 10.1038/s41598-021-85544-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Ikeda M. Reactivation of hepatitis B virus in patients receiving chemotherapy. Jpn J Clin Oncol. 2013;43:8-16. [PMID: 23183929 DOI: 10.1093/jjco/hys191] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
128 Xu X, Huang P, Tian H, Chen Y, Ge N, Tang W, Yang B, Xia J. Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:1273-8. [PMID: 24955456 DOI: 10.1111/jgh.12554] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
129 Yang SS, Hung CT, Li SF, Lee HM, Chung YC, Chen HH, Chang SC. Hepatitis B virus-related mortality in rheumatoid arthritis patients undergoing long-term low-dose glucocorticoid treatment: A population-based study. J Formos Med Assoc 2018;117:566-71. [PMID: 28882423 DOI: 10.1016/j.jfma.2017.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
130 Brasseur M, Heurgué-Berlot A, Barbe C, Brami C, Rey JB, Vella-Boucaud J, Dabouz F, Deslée G, Grange F, Volet J, Bouché O. Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors. BMC Cancer 2015;15:999. [PMID: 26694960 DOI: 10.1186/s12885-015-2033-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
131 Riedell P, Carson KR. A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf 2014;13:977-87. [PMID: 24821316 DOI: 10.1517/14740338.2014.918948] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
132 Daia MT, Median D, Buinoiu NF, Ciocarlan M, Iancu G, Panaitescu AM, Peltecu G, Streinu-Cercel A. COVID-19 Pandemic Impact on Cord Blood Collection for Stem Cell Use and Actual Perspectives. Maedica (Bucur) 2021;16:184-8. [PMID: 34621337 DOI: 10.26574/maedica.2021.16.2.189] [Reference Citation Analysis]
133 Xu L, Tu Z, Xu G, Hu JL, Cai XF, Zhan XX, Wang YW, Huang Y, Chen J, Huang AL. S-phase arrest after vincristine treatment may promote hepatitis B virus replication. World J Gastroenterol 2015; 21(5): 1498-1509 [PMID: 25663769 DOI: 10.3748/wjg.v21.i5.1498] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
134 Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol. 2010;17:32-38. [PMID: 21151407 DOI: 10.3747/co.v17i6.653] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
135 Lim SM, Jang JW, Kim BW, Choi H, Choi KY, Park SJ, Han CW. [Hepatitis B virus reactivation during chlorambucil and prednisolone treatment in an HBsAg-negative and anti-HBs-positive patient with B-cell chronic lymphocytic leukemia]. Korean J Hepatol 2008;14:213-8. [PMID: 18617769 DOI: 10.3350/kjhep.2008.14.2.213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
136 Teplinsky E, Cheung D, Weisberg I, Jacobs RE, Wolff M, Park J, Friedman K, Muggia F, Jhaveri K. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat. 2013;141:167-172. [PMID: 24002736 DOI: 10.1007/s10549-013-2681-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
137 Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012;20:2999-3008. [PMID: 22933131 DOI: 10.1007/s00520-012-1576-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
138 Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 2015;94:1441-50. [PMID: 26193852 DOI: 10.1007/s00277-015-2447-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
139 Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer. 2004;12:191-196. [PMID: 15074316 DOI: 10.1007/s00520-003-0549-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
140 Paccoud O, Surgers L, Lacombe K. [Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach]. Rev Med Interne 2019;40:590-8. [PMID: 30982550 DOI: 10.1016/j.revmed.2019.03.333] [Reference Citation Analysis]
141 Sohn BS, Ahn JH, Jung KH, Ahn SH, Son BH, Gong G, Kim SB. Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine. Jpn J Clin Oncol 2011;41:1059-66. [PMID: 21821601 DOI: 10.1093/jjco/hyr106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
142 Ifuku H, Kusumoto S, Tanaka Y, Totani H, Ishida T, Okada M, Murakami S, Mizokami M, Ueda R, Iida S. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2015;45:1363-1367. [PMID: 25753008 DOI: 10.1111/hepr.12513] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
143 Eren OO, Artac M, Boruban MC, Yavas O, Arslan U, Basaranoglu M. Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Med Oncol 2009;26:386-92. [DOI: 10.1007/s12032-008-9133-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]